Alvotech (ALVO) Other Non Operating Income (2021 - 2026)
Alvotech (ALVO) posted Other Non Operating Income of -$1.3 million for Q1 2026, down 129.53% on a QoQ basis from $4.4 million in Q4 2025, and up 83.67% year-over-year from -$705070.4 in Q1 2025.
Alvotech (ALVO) Other Non Operating Income (2021 - 2026) Analysis & Trends
Alvotech's Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$1.3 million for Q1 2026.
- Quarterly Other Non Operating Income rose 83.67% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.2 million (down 797.86% YoY) and the FY2025 annual result came in at -$16.8 million, down 306.36% from the prior year.
- Other Non Operating Income was -$1.3 million for Q1 2026 at Alvotech, down from $4.4 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $27.6 million in Q2 2022 and bottomed at -$22.9 million in Q1 2022.
- A 5-year average of -$344117.6 and a median of -$1.3 million in 2026 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 957.87% — and 2025, when it tumbled 121502.33%.
- Alvotech's Other Non Operating Income stood at $4.7 million in 2022, then tumbled by 209.25% to -$5.2 million in 2023, then soared by 249.37% to $7.7 million in 2024, then plunged by 43.36% to $4.4 million in 2025, then plunged by 129.53% to -$1.3 million in 2026.
- Business Quant data shows ALVO's Other Non Operating Income at -$1.3 million in Q1 2026, $4.4 million in Q4 2025, and -$1.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | 4.39 Mn |
| Sep 30, 2025 | -1.54 Mn |
| Jun 30, 2025 | -11.75 Mn |
| Mar 31, 2025 | -7.93 Mn |
| Dec 31, 2024 | 7.74 Mn |
| Sep 30, 2024 | -6.09 Mn |
| Jun 30, 2024 | 7.74 Mn |
| Mar 31, 2024 | 6,532.00 |
| Dec 31, 2023 | -5.18 Mn |
| Aug 31, 2023 | -3.08 Mn |
| Jun 30, 2023 | -3.08 Mn |
| Mar 31, 2023 | -1,748.00 |
| Dec 31, 2022 | 4.74 Mn |
| Aug 31, 2022 | 4.74 Mn |
| Jun 30, 2022 | 27.62 Mn |
| Mar 31, 2022 | -22.87 Mn |
| Dec 31, 2021 | -553,000.00 |
| Sep 30, 2021 | 6.85 Mn |